AXIM Biotechnologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXIM research report →
Price Chart
About the company
AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells.
- CEO
- Catalina Valencia
- IPO
- 2014
- Employees
- 7
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on AXIM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.02M
- P/E
- -1.58
- PEG
- -0.11
- P/S
- 2.61
- P/B
- -0.09
- EV/EBITDA
- -13.88
- Div Yield
- 0.00%
- Gross Margin
- -8.71%
- Op Margin
- -268.08%
- Net Margin
- -208.79%
- ROE
- 7.37%
- ROIC
- 36.82%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-427,369-15.7%
- Op Income
- $-1,319,652
- Net Income
- $-1,043,083+70.3%
- EPS
- $-0.00+71.8%
- OCF Growth
- +19.7%
- FCF Growth
- +20.0%
- 52W High
- $0.03
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- -0.11
- RSI (14)
- 47
- Avg Volume
- 382.35K
No earnings-call transcripts are available for AXIM yet.
- Free Float
- 71.6%
- Shares Outstanding
- 340.46M
- Float Shares
- 243.75M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 30, 24 | Valencia Catalina | buy | 1,086,216 |
| Mar 15, 24 | HUEMOELLER JOHN WALTER II | other | 250,000 |
| Mar 15, 24 | Valencia Catalina | other | 7,837,500 |
| Mar 15, 24 | Schroeder Blake | other | 35,000 |
| Mar 15, 24 | Cunningham Robert L | other | 35,000 |
| Mar 15, 24 | Scott Timothy Richard | other | 35,000 |
| Mar 15, 24 | O'Rourke Peter | other | 35,000 |
| Mar 15, 24 | MALASEK ROBERT | other | 53,500 |
| Mar 15, 24 | HUEMOELLER JOHN WALTER II | other | 1 |
| May 23, 23 | Phinney Kurt | other | 2,000,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AXIM coverage
Recent articles, reports, and earnings notes.
No research on AXIM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AXIM report →VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
globenewswire.com · Mar 27
AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
globenewswire.com · Feb 20
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
globenewswire.com · Dec 20
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
businesswire.com · Aug 1
Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
globenewswire.com · Jul 12
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
globenewswire.com · Jul 12
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
globenewswire.com · Oct 12
AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board
globenewswire.com · Oct 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.